Miwako Kobayashi, MD, Nancy M Bennett, MD, Ryan Gierke, MPH, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 2015;64:944-7
Jin J.Pneumococcal Vaccination. JAMA. 2015;313(7):758. doi:10.1001/jama.2015.64.
Pisano J, Cifu AS. Use of Pneumococcal Vaccine in Adults. JAMA. 2015;313(7):719-720. doi:10.1001/jama.2015.63.
CDC released new pneumococcal vaccination recommendations. Adults 65 years of age or older are now recommended to get the pneumococcal conjugate vaccine (PCV13, Prevnar-13®) followed by the pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23) 6-12 months later. Read full article, Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Sept. 19, 2014. (63)37;822-825
The New England Journal of Medicine (NEJM) released the following article, which indicates that vaccinating children against pneumococcal pneumonia cut hospitalizations over the past decade in almost all age groups: Griffin M, Zhu Y, et.al. U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination New England Journal of Medicine (NEJM) (2013) 369:155-163. DOI: 10.1056/NEJMoa1209165